We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

Outcome of subsequent pregnancy after chemotherapy for high risk gestational trophoblastic neoplasia: a case report

Submitted

and 1 other(s)

8 Views
0 Downloads
1 Saves

Presented at

ESGO State of the Art 2018 Conference

-

Presentation

thumbnail

Abstract

Gestational trophoblastic disease is a group of placental disorders that hydatidiform mole is the most common form. It is considered a benign condition that may develop into other malignant forms, referred indistinctly as gestational trophoblastic neoplasia (GTN). Patients with trophoblastic neoplasia are classified by the presence of risk factors according to the International Federation of Gynecology and Obstetrics’ (FIGO) prognostic score having low-risk disease that receiving a single chemotherapy agent and high-risk disease that receiving combination chemotherapy. Adverse effect was reported that influence the outcome of subsequent pregnancy after chemotherapy. A case report of outcome of subsequent pregnancy after three times got etoposide+methotrexate+actinomycin-D alternating with cyclophosphamide+vincristine (EMA/CO) chemotherapy for high risk gestational trophpblastic neoplasia and nine months after that she conceived. During her pregnancy non-invasive prenatal testing (NIPT) was did to screen whether she had fetal abeuploidy and the result was low risk. She delivered at term, born healthy baby. In conclusion, the recommendation interval for subsequent pregnancy after chemotherapy for gestational thropoblastic neoplasm is recomended at least 6 months or more after completion chemotherapy. NIPT is used as a screening method to detect fetal chromosomal aneuploidies.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.